Becker's Healthcare November 19, 2024
Researchers estimate that 136.8 million adults in the U.S. are eligible for semaglutide, the generic for Novo Nordisk’s Ozempic, Wegovy and Rybelsus.
In a study published Nov. 18 in JAMA, researchers from Beth Israel Deaconess Medical Center and Harvard Medical School, both based in Boston, and Chicago-based Northwestern University quantified the eligibility of the popular therapies.
Using a randomized sample of nonpregnant adults, they analyzed the prevalence of Type 2 diabetes, weight loss management and cardiovascular disease. Ozempic and Rybelsus treat diabetes, and Wegovy is for chronic weight management and cardiovascular events.
In those 136.8 million people, many conditions overlapped. About 22.8 million self-reported diabetes and either obesity (a body mass index of 30 or above) or diabetes and...
Today's Sponsors
Today's Sponsor